Tango Therapeutics, Inc. Operating Expenses
Tango Therapeutics, Inc. (TNGX) reported Operating Expenses of $59.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- Tango Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $59.78M, a 35.42% increase year-over-year.
- Tango Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $48.77M, a 1.77% increase year-over-year.
- Tango Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $41.86M, a 7.02% decline year-over-year.
- Tango Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $39.74M, a 10.67% decline year-over-year.
- Tango Therapeutics, Inc. operating expenses for fiscal 2025 was $173.67M, a 7.46% decline from fiscal 2024.
- Tango Therapeutics, Inc. operating expenses for fiscal 2024 was $187.66M, a 24.53% increase from fiscal 2023.
- Tango Therapeutics, Inc. operating expenses for fiscal 2023 was $150.70M, a 10.87% increase from fiscal 2022.
- Tango Therapeutics, Inc. operating expenses for fiscal 2022 was $135.93M, a 42.74% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $59.78M 10-Q · filed 2026-08-11 | $108.56M 10-Q · filed 2026-08-11 | $150.42M derived: sum of 3 quarters · filed 2026-08-11 | $190.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $48.77M 10-Q · filed 2026-05-13 | $90.63M derived: sum of 2 quarters · filed 2026-05-13 | $130.37M derived: sum of 3 quarters · filed 2026-05-13 | $174.52M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $41.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $81.60M derived: sum of 2 quarters · filed 2026-03-05 | $125.75M derived: sum of 3 quarters · filed 2026-08-11 | $173.67M 10-K · filed 2026-03-05 |
| 2025-09-30 | $39.74M 10-Q · filed 2025-11-04 | $83.89M derived: sum of 2 quarters · filed 2026-08-11 | $131.81M 10-Q · filed 2025-11-04 | $176.84M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $44.15M 10-Q · filed 2026-08-11 | $92.07M 10-Q · filed 2026-08-11 | $137.10M derived: sum of 3 quarters · filed 2026-08-11 | $181.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $47.92M 10-Q · filed 2026-05-13 | $92.95M derived: sum of 2 quarters · filed 2026-05-13 | $137.43M derived: sum of 3 quarters · filed 2026-05-13 | $186.86M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $45.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $89.51M derived: sum of 2 quarters · filed 2026-03-05 | $138.94M derived: sum of 3 quarters · filed 2026-03-05 | $187.66M 10-K · filed 2026-03-05 |
| 2024-09-30 | $44.48M 10-Q · filed 2025-11-04 | $93.91M derived: sum of 2 quarters · filed 2025-11-04 | $142.64M 10-Q · filed 2025-11-04 | $183.08M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $49.43M 10-Q · filed 2025-08-05 | $98.15M 10-Q · filed 2025-08-05 | $138.60M derived: sum of 3 quarters · filed 2026-03-05 | $174.96M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $48.73M 10-Q · filed 2025-05-12 | $89.17M derived: sum of 2 quarters · filed 2026-03-05 | $125.53M derived: sum of 3 quarters · filed 2026-03-05 | $163.37M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $40.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $76.80M derived: sum of 2 quarters · filed 2026-03-05 | $114.65M derived: sum of 3 quarters · filed 2026-03-05 | $150.70M 10-K · filed 2026-03-05 |
| 2023-09-30 | $36.36M 10-Q · filed 2024-11-06 | $74.20M derived: sum of 2 quarters · filed 2024-11-06 | $110.26M 10-Q · filed 2024-11-06 | $147.23M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $37.84M 10-Q · filed 2024-08-07 | $73.90M 10-Q · filed 2024-08-07 | $110.88M derived: sum of 3 quarters · filed 2025-02-27 | $147.72M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $36.05M 10-Q · filed 2024-05-08 | $73.03M derived: sum of 2 quarters · filed 2025-02-27 | $109.87M derived: sum of 3 quarters · filed 2025-02-27 | $140.85M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $36.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $73.82M derived: sum of 2 quarters · filed 2025-02-27 | $104.79M derived: sum of 3 quarters · filed 2025-02-27 | $135.93M 10-K · filed 2025-02-27 |
| 2022-09-30 | $36.84M 10-Q · filed 2023-11-08 | $67.82M derived: sum of 2 quarters · filed 2023-11-08 | $98.95M 10-Q · filed 2023-11-08 | $126.65M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $30.97M 10-Q · filed 2023-08-07 | $62.11M 10-Q · filed 2023-08-07 | $89.81M derived: sum of 3 quarters · filed 2023-08-07 | $116.17M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $31.14M 10-Q · filed 2023-05-09 | $58.84M derived: sum of 2 quarters · filed 2023-05-09 | $85.19M derived: sum of 3 quarters · filed 2023-05-09 | $107.90M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $27.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $54.06M derived: sum of 2 quarters · filed 2023-03-27 | $76.77M derived: sum of 3 quarters · filed 2023-03-27 | $95.23M 10-K · filed 2023-03-27 |
| 2021-09-30 | $26.36M 10-Q · filed 2022-11-10 | $49.06M derived: sum of 2 quarters · filed 2022-11-10 | $67.53M 10-Q · filed 2022-11-10 | $85.61M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $22.71M 10-Q · filed 2022-08-10 | $41.18M 10-Q · filed 2022-08-10 | $59.26M derived: sum of 3 quarters · filed 2022-08-10 | $74.75M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $18.47M 10-Q · filed 2022-05-11 | $36.55M derived: sum of 2 quarters · filed 2022-05-11 | $52.04M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $18.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $33.57M derived: sum of 2 quarters · filed 2022-03-28 | $59.86M 10-K · filed 2022-03-28 | |
| 2020-09-30 | $15.49M 10-Q · filed 2021-11-09 | $41.78M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |